FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
About | Sample | Privacy
Related Topics >> FDA | Regulators | Sanofi Aventis | antibiotic | Ketek

SPOTLIGHT: FDA panel votes to restrict Ketek


An FDA advisory panel has voted to restrict the use of Sanofi-Aventis' controversial antibiotic Ketek. Panel members said that the risks outweighed the benefits of using Ketek against acute bacterial sinusitis and acute bacterial exacerbation of chronic bronchitis. Report

More stories about antibiotic   Ketek   FDA   Regulators   Sanofi Aventis  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 20 + 3?
To combat spam, please solve the math question above.